242 related articles for article (PubMed ID: 23084531)
1. Advanced clinical states in prostate cancer.
Cheng HH; Lin DW; Yu EY
Urol Clin North Am; 2012 Nov; 39(4):561-71. PubMed ID: 23084531
[TBL] [Abstract][Full Text] [Related]
2. [Castration resistant prostate cancer 2011].
Miller K
Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
[TBL] [Abstract][Full Text] [Related]
3. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
Berenguer Sánchez A
Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
[No Abstract] [Full Text] [Related]
4. Complete androgen blockade for the treatment of prostate cancer.
Labrie F; Dupont A; Belanger A
Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
[No Abstract] [Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer.
Bahnson R
J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
[No Abstract] [Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. [Promising on advanced cancer, several new drugs coming].
Widmark A; Karlsson CT
Lakartidningen; 2012 Feb 22-28; 109(8):416-9. PubMed ID: 22509668
[No Abstract] [Full Text] [Related]
8. [Strategy in advanced castration-resistant prostate cancer].
Gross-Goupil M; Roca S; Pasticier G; Ravaud A
Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW; Xie W; Regan MM; Pomerantz M; Nakabayashi M; Daskivich TJ; Sartor O; Taplin ME; Kantoff PW; Oh WK
Cancer; 2008 Mar; 112(6):1247-53. PubMed ID: 18293426
[TBL] [Abstract][Full Text] [Related]
10. Managing advanced prostate cancer: the rapidly changing treatment landscape.
Dreicer R
Am J Manag Care; 2014 Dec; 20(12 Suppl):S282-9. PubMed ID: 25734964
[TBL] [Abstract][Full Text] [Related]
11. What to do if prostate cancer returns.
Johns Hopkins Med Lett Health After 50; 2001 Dec; 13(10):6-7. PubMed ID: 11727445
[No Abstract] [Full Text] [Related]
12. Castration refractory prostate cancer: cinderella finally comes to the ball.
Chowdhury S; Harper P; Powles T
Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
[No Abstract] [Full Text] [Related]
13. The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy.
Soloway MS
Prog Clin Biol Res; 1990; 350():141-8. PubMed ID: 2201040
[No Abstract] [Full Text] [Related]
14. Systemic therapeutic strategies for prostate cancer.
Nelson WG
Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
[No Abstract] [Full Text] [Related]
15. How should we understand the term androgen deprivation therapy?
Drewa T; Soloway MS
Eur Urol; 2012 Apr; 61(4):856. PubMed ID: 22266269
[No Abstract] [Full Text] [Related]
16. Treatment options in androgen-independent prostate cancer.
Lara PN; Meyers FJ
Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of castration-resistant prostate cancer].
Petrányi Á
Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
[TBL] [Abstract][Full Text] [Related]
18. Castration-refractory prostate cancer: new therapies, new questions.
Appleman LJ
Oncology (Williston Park); 2010 Dec; 24(14):1318-9, 1326. PubMed ID: 21294476
[No Abstract] [Full Text] [Related]
19. Testosterone measurement in patients with prostate cancer.
Schulman CC; Irani J; Morote J; Schalken JA; Montorsi F; Chlosta PL; Heidenreich A
Eur Urol; 2010 Jul; 58(1):65-74. PubMed ID: 20434831
[TBL] [Abstract][Full Text] [Related]
20. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Climent MA; Piulats JM; Sánchez-Hernández A; Arranz JÁ; Cassinello J; García-Donas J; González del Alba A; León-Mateos L; Mellado B; Méndez-Vidal MJ; Pérez-Valderrama B;
Crit Rev Oncol Hematol; 2012 Sep; 83(3):341-52. PubMed ID: 22285697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
